A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer - Hirooka, Yoshiki; Kasuya, Hideki; Ishikawa, Takuya; Kawashima, Hiroki; Ohno, Eizaburo; Villalobos, Itzel B.; Naoe, Yoshinori; Ichinose, Toru; Koyama, Nobuto; Tanaka, Maki; Kodera, Yasuhiro; Goto, Hidemi (BMC cancer, 2018)
Keywords: Adult; Aged; Analysis; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Antitumor activity; Cancer therapies; Care and treatment; Chemotherapy; Clinical trials; Combined Modality Therapy - adverse effects; Combined Modality Therapy - methods; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; Drug dosages; Duodenum; Endosonography; Erlotinib Hydrochloride - therapeutic use; EUS-guidance; Female; Gemcitabine; Herpes simplex; Herpesvirus 1, Human - genetics; HF10; Humans; Injection; Injections, Intralesional - methods; Male; Medical prognosis; Metastasis; Middle Aged; Mutation; Myelosuppression; Oncolysis; Oncolytic viral therapy; Oncolytic Virotherapy - adverse effects; Oncolytic Virotherapy - methods; Oncolytic virus; Oncolytic Viruses - genetics; Pancreas - diagnostic imaging; Pancreas - pathology; Pancreatic cancer; Pancreatic Neoplasms; Pancreatic Neoplasms - mortality; Pancreatic Neoplasms - pathology; Pancreatic Neoplasms - therapy; Patients; Prognosis; Progression-Free Survival; Survival; Survival Rate; Toxicity; Treatment Outcome; Tumors; Ultrasonography, Interventional; Ultrasound; Young Adult; Oncolytic virus; EUS-guidance; HF10; Pancreatic cancer